| 36th week of 2013 patent applcation highlights part 28 |
| Patent application number | Title | Published |
|---|
| 20130230456 | PAPILLOMAVIRUS PSEUDOVIRUSES FOR DETECTION AND THERAPY OF TUMORS - Disclosed herein are methods of detecting tumors, monitoring cancer therapy, and selectively inhibiting the proliferation and/or killing of cancer cells utilizing a papilloma pseudovirus or a papilloma virus-like particle (VLP) | 2013-09-05 |
| 20130230457 | Thermosensitive Nanoparticle Formulations and Method of Making The Same - The present invention relates to a formulation of thermosensitive liposomes, and more specifically to a formulation of liposomes comprising phospholipids and a surface active agent, wherein the liposomes support long term storage at temperatures less than or equal to about 8° C., control degradate formation to maximize product potency and release their contents at mild hyperthermic temperatures. Methods of making formulations are also described. | 2013-09-05 |
| 20130230458 | Cell Permeable Inhibitors of Anaphase Promoting Complex - The invention provides compositions and methods for treating cell cycle disorders. Compositions of the invention include proTAME, a prodrug analog of TAME, and, optionally, one or more therapeutic agents. | 2013-09-05 |
| 20130230459 | RADIOLABELLED mGluR2 PET LIGANDS - The present invention relates to novel, selective, radiolabelled mGluR2 ligands which are useful for imaging and quantifying the metabotropic glutamate receptor mGluR2 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a host, in vitro or in vivo and to precursors of said compounds. | 2013-09-05 |
| 20130230460 | USE OF CYANINE DYES FOR THE DETECTION OF TAU FOR DIAGNOSIS OF EARLY-STAGE TAUOPATHIES - Radiolabeled compounds useful as diagnostic imaging agents of Tau pathology in Alzheimer's disease are described. Compositions and methods of making such compounds are also described. | 2013-09-05 |
| 20130230461 | Piggy-Back Delivery of Nucleic Acids Into Organisms - The present invention includes nucleic acid hybrid molecules capable of entering cells comprising at least one vivo-morpholino oligonucleotide (vivo-MO) comprising a guanidine-rich head conjugated to the 5′ end, and at least one standard oligonucleotide comprising a gene-specific sequence and a standard oligonucleotide pairing sequence, wherein the standard oligonucleotide is bound to the vivo-morpholino oligonucleotide through base pairing to form a hybrid and wherein the vivo-morpholino oligonucleotide pairing sequence is complementary to the standard oligonucleotide pairing sequence. | 2013-09-05 |
| 20130230462 | METHOD FOR PREDICTING AND PREVENTING CARDIOVASCULAR DISEASE - Disclosed are methods of identifying an individual having a predisposition to the development of a cardiovascular disease, and administering a suitable prophylactic agent to the identified individual to prevent disease. Methods of screening and identifying agents that inhibit bacterial collagen binding protein (CBP)-mediated cell invasion are also disclosed. | 2013-09-05 |
| 20130230463 | SUPERPARAMAGNETIC NANOPARTICLES WITH PEG SUBSTITUTED alpha-HYDROXY PHOSPHONATE SHELLS - The present application discloses nanoparticles, particularly nanoparticles of superparamagnetic iron oxide, which find utility in iron therapy and diagnostic imaging such as magnetic resonance (MR). The disclosed nanoparticles have been treated with an α-hydroxyphosphonic acid conjugate containing polyethylene glycol as a hydrophilic moiety to render the nanoparticles sufficiently hydrophilic to find utility in diagnostic imaging. Among the modified hydrophilic nanoparticles disclosed are those in which the hydrophilic moieties of the modifying conjugate are polyethylene oxide-based polymers and have a molecular weight greater than 5,000 dalton and less than or equal to about 30,000 daltons. Surprisingly, these nanoparticles have a more rapid and complete processing in liver of retained nanoparticles when compared to similar nanoparticles in which the PEG-based hydrophilic moiety has a molecular weight less than 5,000. | 2013-09-05 |
| 20130230464 | Imaging Probe Including Nanoparticle - An imaging probe can include a photoluminescent carbon nanostructure configured to emit a wavelength of light detectable through living tissue, and a targeting moiety including a first binding partner configured to interact with a second binding partner. | 2013-09-05 |
| 20130230465 | BENZOCYANINE COMPOUNDS - Compounds useful as labels with properties comparable to known fluorescent compounds. The compounds are conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided. | 2013-09-05 |
| 20130230466 | CYANINE COMPOUNDS - Compounds used as labels with properties comparable to known fluorescent compounds. The compounds can be conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided. | 2013-09-05 |
| 20130230467 | POLYMERIZED MICELLES FOR DIAGNOSIS - The invention relates to polymerized micelles of size inferior to 100 nm for in vivo diagnosis, in particular of cancer. The polymerized micelles of the invention comprise a diagnostic agent and an amphiphilic polymer obtainable by the polymerization of an amphiphilic monomer, said monomer comprising: a lipophilic chain comprising a polymerizable vinylic or diacetylenic group, and a hydrophilic head comprising a polyoxyethylene or polyoxypropylene chain. The invention finds application in the pharmaceutical field, in particular. | 2013-09-05 |
| 20130230468 | ISOTOPICALLY LABELED DEOXY-GLUCOSE AND DERIVATIVES THEREOF, COMPOSITIONS COMPRISING THEM AND USES THEREOF - The present invention provides isotopically labeled deoxy-glucose and derivatives thereof, methods of their preparation, ration, kits comprising them and uses thereof for spin hyperpolarized magnetic resonance imaging, utilized in the quantitative and qualitative diagnosis of states, conditions, diseases, or disorders in the body of a subject. | 2013-09-05 |
| 20130230469 | Oral Care Product and Methods of Use and Manufacture Thereof - This invention relates to a mouthwash comprising an aqueous solution of an effective amount of an orally acceptable, soluble zinc salt together with an effective amount of a preservative selected from methylisothiazolinone (MIT), benzyl alcohol, glycerol monocaprylate, and combinations thereof; as well as to methods of using and of making such compositions. | 2013-09-05 |
| 20130230470 | PET FOOD COMPOSITION - Pet food comprising trisodium L-ascorbic acid-2-monophosphate (STAY-C50) or sodium-calcium L-ascorbic acid-2monophosphate (STAY-C35), or mixtures thereof and, optionally, a polymer (for fixation of the ascorbate on the dental surface) and use 5 thereof as additive to pet food for preventing or treating calculus, plaque, gingivitis and periodontal disease and for enhancing the antioxidative capacity in the whole organism. | 2013-09-05 |
| 20130230471 | Personal Care Compositions with Acidified Pectins - Personal care compositions are provided that include acidified pectins at a concentration of about 2 to about 5% by weight. The acidified pectin includes a low ester pectin with a degree of esterification of about 30 to about 50 and a pH of about 2 to about 4. Desirably, the personal care composition is characterized as a viscous, fluid gel. Also provided are methods for preparing personal care compositions and methods for the use of personal care formulations. | 2013-09-05 |
| 20130230472 | BONDING TISSUES AND CROSS-LINKING PROTEINS WITH NAPHTHALIMIDE COMPOUNDS - Naphthalimide compounds are used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bond tissues and other biomaterials together. A naphthalimide-labeled biomolecule, such as a naphthalimide-labeled chitosan, is also capable of bonding tissues without subsequent direct illumination of the contacted tissue area. The naphthalimide compounds may be used in tissue or arterial repair, stabilization of an expanded arterial wall after angioplasty, tethering pharmaceutical agents to tissue surfaces to provide local drug delivery, and for chemically bonding skin care products, sunscreens, and cosmetics to the skin. | 2013-09-05 |
| 20130230473 | USE OF SUBSTITUTED METHOXYALKOXYPHENYLALKYL DERIVATIVES AS PRESERVATIVE, PRESERVING METHOD, COMPOUNDS AND COMPOSITION - The present invention relates to the use as a preserving agent, in particular in cosmetic or dermatological composition, of at least one compound of formula (I): in which:—X represents ═O or —OH;—R1 represents a hydrogen atom or a methyl;—R2 represents a hydrogen atom, a methyl or an ethyl;—R3 represents a C1-C12, saturated or unsaturated, linear hydrocarbon-based radical, optionally substituted with a hydroxyl group (OH); with the exclusion of the compound of formula (I) in which X represents ═O, R1=methyl, R2=H and R3=—(CH | 2013-09-05 |
| 20130230474 | Sunscreen Composition Comprising UV Composite - A sunscreen composition is herein described in the form of an emulsion comprising an oil phase, and aqueous phase, and a UV composite comprising a silicone elastomer swollen in a liquid UV active. The ratio of liquid UV active to silicone elastomer in the UV composite may vary from 1:1 to 8:1. The liquid UV active include solubilized solid UV actives. Further described herein is a SPF enhancing UV composite for addition to a sunscreen composition. Methods of making the aforementioned sunscreen composition and SPF enhancing UV composite are described herein. | 2013-09-05 |
| 20130230475 | ANTIPERSPIRANT EMULSION PRODUCTS AND PROCESSES FOR MAKING THE SAME - A water in oil emulsion composition includes an antiperspirant active, an emulsifier, and a combination of polyalkylene glycols making up between about 1 and about 12 wt. % of the total composition. The combination includes H[OCH | 2013-09-05 |
| 20130230476 | Fragrance Compositions Comprising Special Mixtures of Diastereomers of 2-Isobutyl-4-Methyl-Tetrahydro-2H-Pyran-4-OL - The present invention relates to a fragrance composition comprising a mixture of diastereomers of 2-isobutyl-4-methyl-tetrahydro-2H-pyran-4-ol, which comprises more than 95 wt. % of the optically inactive cis-racemate and less than 5 wt. % of the optically inactive trans-racemate. The present invention further relates to a method for producing a perfumed product or article as well as perfumed or aromatized articles comprising the fragrance compositions of the present invention. | 2013-09-05 |
| 20130230477 | SWELLABLE COSMETIC SYSTEMS - The invention relates to a cosmetic system comprising a basecoat composition comprising at least one acrylic thickener and a topcoat composition comprising at least one aqueous polyurethane dispersion. | 2013-09-05 |
| 20130230478 | MASCARA COMPOSITIONS CONTAINING AN OIL-DISPERSIBLE MICRONIZED WAX - The invention relates to a mascara composition comprising at least one oil-dispersible micronized wax which, if desired, can be processed at room temperature. | 2013-09-05 |
| 20130230479 | Perfume Compositions - Perfume compositions effective against urine malodour and having a low odour, comprise between 20% and 50% of perfume ingredients comprising at least 15% by-weight of N-ethyl-N- (3-methylphenyl) propanamide. | 2013-09-05 |
| 20130230480 | WATER DISPERSION TYPE SUSTAINED RELEASE PREPARATION FOR RELEASING VOLATILE ACTIVE SUBSTANCE - There is provided a a sustained release preparation including a dispersion for a sustained release preparation and a volatile active substance, the dispersion having viscosity at 25° C. of not more than 100 mPa·s and including polymer particles which are obtained by polymerizing ethylenically unsaturated group-containing monomers (A), polyvinyl alcohol (C1) in an amount of more than 0% by weight but not more than 30% by weight relative to a total amount of the ethylenically unsaturated group-containing monomers (A), having a degree of saponification of more than 82 mol % but not more than 91.5 mol %, polyvinyl alcohol (C3) in an amount of more than 0% by weight but not more than 30% by weight relative to the total amount of the ethylenically unsaturated group-containing monomers (A), having a degree of saponification of not less than 98 mol %, and water. | 2013-09-05 |
| 20130230481 | WATER DISPERSION TYPE SUSTAINED RELEASE PREPARATION FOR RELEASING VOLATILE ACTIVE SUBSTANCE - There is provided a water dispersion for a sustained release preparation, the dispersion having viscosity at 25° C. of not more than 100 mPa·s and including polymer particles which are obtained by polymerizing ethylenically unsaturated group-containing monomers (A), polyvinyl alcohol (C2) in an amount of more than 0% by weight but not more than 50% by weight relative to a total amount of the ethylenically unsaturated group-containing monomers (A), having a degree of saponification of more than 91.5 mol % and less than 98 mol %, and water. There is also provided a sustained release preparation including the water dispersion and a volatile active substance which is selected from a group consisting of a pheromone substance, an agricultural chemical, an aromatic, a deodorant and an antibacterial agent. | 2013-09-05 |
| 20130230482 | WATER DISPERSION TYPE SUSTAINED RELEASE PREPARATION FOR RELEASING VOLATILE ACTIVE SUBSTANCE - There is provided a water dispersion for a sustained release preparation, the dispersion having viscosity at 25° C. of not more than 100 mPa·s and including polymer particles which are obtained by polymerizing ethylenically unsaturated group-containing monomers (A); at least one kind of a hydrophilic substance (B) in an amount of more than 0% by weight but not more than 20% by weight relative to a total amount of the ethylenically unsaturated group-containing monomers (A), being selected from a group consisting of a surfactant, a plasticizer and a moisturizer; polyvinyl alcohol (C) in an amount of more than 0% by weight but not more than 30% by weight relative to a total amount of the ethylenically unsaturated group-containing monomers (A), having a degree of saponification of more than 82 mol %; and water. | 2013-09-05 |
| 20130230483 | FUSION MOLECULE BASED ON NOVEL TAA VARIANT - This invention provides novel carbonic anhydrase (CAIX) nucleic acid and peptide sequences, as well as related methods and compositions, including anti-cancer immunogenic agent(s) (e.g. vaccines and chimeric molecules) that elicit an immune response specifically directed against cancer cells expressing a CAIX antigenic marker. The novel CAIX variant and related compositions are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, adoptive immunotherapy. | 2013-09-05 |
| 20130230484 | Interleukin-1 Conjugates and Uses Thereof - The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen array, wherein the antigen is an IL-1 protein, an IL-1 mutein or an IL-1 fragment. More specifically, the invention provides a composition comprising a virus-like particle, and at least one IL-1 protein, IL-1 mutein or at least one IL-1 fragment linked thereto. The invention also provides a process for producing the composition. The compositions of the invention are useful in the production of vaccines for the treatment of inflammatory diseases, and chronic autoimmune diseases, genetic diseases and cardiovascular diseases. The composition of the invention efficiently induces immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context. | 2013-09-05 |
| 20130230485 | Methods for Treating Patients Undergoing Multi-Cycle Chemotherapy - The present invention provides methods for treating a patient undergoing multi-cycle chemotherapy that provides significantly improved platelet counts in the patients, and facilitates retention of dose intensity from cycle to cycle of the chemotherapy. | 2013-09-05 |
| 20130230486 | COMPOSITIONS AND METHODS TO INDUCE TARGETED APOPTOSIS - Embodiments herein concern compositions and methods for treating a subject having or suspected of developing a pulmonary disorder or cancer. Certain embodiments concern modulating protein tyrosine phosphatase non-receptor type 13 (PTP-N13) expression and/or activity in a subject to treat uncontrolled cellular growth in the subject. | 2013-09-05 |
| 20130230487 | Immunomodulatory Methods and Systems for Treatment and/or Prevention of Hypertension - Immunomodulatory agents, T cell, compositions, methods and systems for treating and/or preventing hypertension and/or a condition associated thereto in an individual. | 2013-09-05 |
| 20130230488 | METHOD FOR INDUCING IMMUNITY WITH A PEPTIDE FRAGMENT FROM HUMAN CAPRIN-1 - The invention relates to an immunity-inducing agent comprising, as an active ingredient, at least one polypeptide having immunity-inducing activity that is selected from among polypeptides (a), (b), and (c): (a) a polypeptide of at least seven contiguous amino acids of the amino acid sequence shown by any even SEQ ID number selected from SEQ ID NOs: 2 to 30 listed in the Sequence Listing; (b) a polypeptide of at least seven amino acids having 90% or more sequence identity with the polypeptide (a); and (c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence thereof, or a recombinant vector comprising a polynucleotide encoding said polypeptide and capable of expressing said polypeptide in vivo. | 2013-09-05 |
| 20130230489 | Paediatric Compositions For Treating Multiple Sclerosis - The present invention relates to pharmaceutical compositions comprising a 2-amino-2-[2-(4-C | 2013-09-05 |
| 20130230490 | PEG-Interferon Lambda 1 Conjugates - The present application discloses new PEG-interferon lambda 1 conjugates (PEG-IFNλ1), processes for their preparation, pharmaceutical compositions containing these conjugates and processes for making the same. These conjugates have increased blood half-lives and persistence time compared to IFNλ1 and are effective in the treatment of hepatitis B and hepatitis C. | 2013-09-05 |
| 20130230491 | COVALENTLY IMMOBILIZED PROTEIN GRADIENTS IN THREE-DIMENSIONAL POROUS SCAFFOLDS - The invention provides a method for forming an immobilized agent gradient within a 3-dimensional porous scaffold. A 3-dimensional scaffold formed from a biocompatible material is provided. The surface of the scaffold and/or the agent is activated so as to allow binding of the agent to the scaffold. The activated scaffold is contacted with a solution containing the agent. Contact with the solution is maintained for a sufficient period of time to allow diffusion of the solution through a portion of the scaffold, thereby forming a desired gradient of the agent through the 3-dimensional scaffold. | 2013-09-05 |
| 20130230492 | GENETIC INHIBITION BY DOUBLE-STRANDED RNA - A process is provided of introducing an RNA into a living cell to inhibit gene expression of a target gene in that cell. The process may be practiced ex vivo or in vivo. The RNA has a region with double-stranded structure. Inhibition is sequence-specific in that the nucleotide sequences of the duplex region of the RNA and of a portion of the target gene are identical. The present invention is distinguished from prior art interference in gene expression by antisense or triple-strand methods. | 2013-09-05 |
| 20130230493 | PHOTOCROSSLINKED BIODEGRADABLE HYDROGEL - A photocrosslinked biodegradable hydrogel includes a plurality of natural polymer macromers cross-linked with a plurality of hydrolyzable acrylate cross-links. The hydrogel is cytocompatible and produces substantially non-toxic products upon degradation. | 2013-09-05 |
| 20130230494 | Cellular Preparations For Wound Management - Disclosed herein are methods of preserving or preparing cell-based compositions for use in wound management. The methods can be carried out by steps including: (a) providing skin cells; (b) treating the skin cells with a monosaccharide; (c) treating the skin cells with a disaccharide; and (d) lyophilizing the skin cells. | 2013-09-05 |
| 20130230495 | AMPHIPHILIC CHITOSAN NANOGEL AS AN INJECTABLE DELIVERY SYSTEM FOR STEM CELL THERAPY - The present invention relates to a novel injectable delivery system for stem cell therapy, which comprises a thermo-sensitive amphiphlic chitosan nanogel. Therefore, the invention provides a method for repairing a tissue damage of a subject using the amphiphlic chitosan nanogel served as a carrier for delivering the stem cells to the damaged tissue. This invention also provides a method for sustaining the growth of stem cells using the amphiphlic chitosan nanogel served as a niche or scaffold. | 2013-09-05 |
| 20130230496 | GRAPHENE HYDROGEL AND METHOD FOR USING THE SAME - Provided herein is a hydrogel composition comprising a graphene, a chitosan, and a polyethylene (glycol) diacrylate (PEGDA) (PCG hydrogel). In some embodiments, the hydrogel further comprises a N-isopropylacrylamide (NIPAM) (TPCG hydrogel). Also provided is a method for differentiating a mesenchymal stem cell comprising contacting the cell with the PCG hydrogel. Further provided herein is a method for delivering a pharmaceutical composition to a cell comprising administering to the cell a TPCG hydrogel and the pharmaceutical composition. | 2013-09-05 |
| 20130230497 | Renovation And Repopulation Of Decellularized Tissues And Cadaveric Organs By Stem Cells - A method of manufacturing a tissue matrix for implantation into a patient is disclosed. The method sets forth collecting embryonic stem cells from a placenta which has been treated to remove residual cord blood and seeding the collected stem cells onto or into a tissue matrix. The seeded tissue matrix is then implanted on or into a patient. The seeded tissue matrix made by the method of the present invention is also disclosed. | 2013-09-05 |
| 20130230498 | REDUCING SHORT-CHAIN FATTY ACIDS AND ENERGY UPTAKE IN OBESE HUMANS BY MANAGING THEIR INTESTINAL MICROBIAL COMMUNITIES - The present invention provides for microbial compositions and methods for reducing the concentration of short-chain fatty acids in the gut as a way to reduce energy uptake and manage obesity. More specifically, the invention provides for decreasing short-chain fatty acids available for absorption in the human gut, such as acetate, using one or more of: a probiotic including a homo-acetogenic, acetate oxidizing bacterium that converts acetate to H | 2013-09-05 |
| 20130230499 | CELLULAR BLOOD MARKERS FOR EARLY DIAGNOSIS OF ALS AND FOR ALS PROGRESSION - The present invention provides methods for early diagnosis of amyotrophic lateral sclerosis (ALS) and for determining the efficacy of a treatment for ALS in an ALS patient, i.e., monitoring ALS progression, utilizing cellular blood markers; as well as kits for carrying out these methods. | 2013-09-05 |
| 20130230500 | Botulinum Toxin for Smoking Cessation - The invention provides for the use of any form of botulinum toxin, or any enzymatically active derivative thereof, to cause temporary paralysis of the muscles of the lips of the mouth to promote smoking cessation. | 2013-09-05 |
| 20130230501 | Cycloalkyl-Substituted Imidazole Derivative - A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc; R | 2013-09-05 |
| 20130230502 | METHODS OF TREATING CANCER USING OPIOD RETARGETED ENDOPEPIDASES - The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions. | 2013-09-05 |
| 20130230503 | METHOD AND PREPARATION FOR THE TREATMENT OR PREVENTION OF ANXIETY OR NEUROGENESIS - The present invention relates to the use of a preparation, especially a nutritional preparation, for the prevention or treatment of anxiety in a subject, especially in a depressed subject, and depression. More specifically, the present invention relates to the use of a preparation, especially a nutritional preparation, for the prevention or treatment of anxiety or depression in a subject that is non-responsive to SSRI medication. Furthermore, the invention relates to the use of a preparation, especially anutritional preparation, for regulating neurogenesis. The preparation comprises the following components: a) at least one ω-3 polyunsaturated fatty acid (PUFA); b) at least two phospholipids, selected from the group consisting of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine or any mixture thereof; and c) one or more compounds which are a factor in the serotonin metabolism, selected from the group of B vitamins and tryptophan. | 2013-09-05 |
| 20130230504 | PEPTIDE ANTAGONISTS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND METHODS OF USE THEREOF - The present invention provides isolated polypeptides having VEGF antagonist activity, pharmaceutical compositions and methods of treatment. The polypeptides of the invention include polypeptides comprising a portion of SEQ ID NO: 1 having VEGF antagonist activity, polypeptides comprising SEQ ID NO: 2 or a portion thereof having VEGF antagonist activity, and a polypeptide having the structure of formula (I), set forth above. The present invention further includes analogs and derivatives of these polypeptides having VEGF antagonist activity. | 2013-09-05 |
| 20130230505 | INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF GLUTAMINYL-TRNA SYNTHETASES - Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. | 2013-09-05 |
| 20130230506 | METHODS FOR INCREASING INTRACELLULAR ACTIVITY OF HSP70 - The present invention relates to a bioactive agent capable of increasing the intracellular concentration and/or activity of Hsp70 for use in the treatment of a lysosomal storage disease which arise from a defect in an enzyme whose activity is not directly associated with the presence of lysosomal BMP as a co-factor; such as glycogen storage diseases, gangliosidoses, neuronal ceroid lipofuscinoses, cerebrotendinous cholesterosis, Wolman's disease, cholesteryl ester storage disease, disorders of glycosaminoglycan metabolism, mucopolysaccharidoses, disorders of glycoprotein metabolism, mucolipidoses, aspartylglucosaminuria, fucosidosis, mannosidoses, and sialidosis type II. | 2013-09-05 |
| 20130230507 | INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF P38 MULTI-TRNA SYNTHETASE COMPLEX - Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. | 2013-09-05 |
| 20130230508 | INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-tRNA SYNTHETASES - Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. | 2013-09-05 |
| 20130230509 | AGENT FOR NEUROPATHIC PAIN - An object of the present invention is to provide a substance which can be used as an active ingredient for improving neuropathic pain having a novel mechanism of action different from those of currently available agents and, therefore, provide an improving agent for neuropathic pain which rarely interacts with currently available agents and also does not have adverse reactions similar to those of currently available agents. An improving agent for neuropathic pain due to a hyperalgesic response of the present invention as a means for resolution is characterized by comprising, as an active ingredient, a lyase (an elimination enzyme) which has an activity of degrading a chondroitin sulfate chain of a chondroitin sulfate proteoglycan, and is typified by chondroitinase ABC which selectively removes chondroitin sulfate and dermatan sulfate of a proteoglycan. | 2013-09-05 |
| 20130230510 | METHOD OF INHIBITION OF LEUKEMIC STEM CELLS - A method for inhibition of leukemic stem cells expressing IL-3R.alpha.; (CD 123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3R.alpha. (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule. | 2013-09-05 |
| 20130230511 | BIOMARKERS FOR RESPONSE TO TYROSINE KINASE PATHWAY INHIBITORS IN CANCER - Copy number gains detected in tumors and associated with drug sensitivity and resistance in vivo and in vitro can be used as biomarkers to select, predict and monitor drug treatment outcomes in cancer patients treated with tyrosine kinase inhibitors. Methods to identify patients with NSCLC or other malignancies who are more likely to benefit from tyrosine kinase inhibitors such as VEGF or VEGFR inhibitors when used either as monotherapy or in combination with other therapies such as chemotherapy or EGFR inhibitors, and who are in the advanced stages of disease and/or who have undergone adjuvant therapy are also provided herein. | 2013-09-05 |
| 20130230512 | INHIBITORS OF THE ATB(0,+) TRANSPORTER AND USES THEREOF - The present invention includes inhibitors of the amino acid transporter ATB | 2013-09-05 |
| 20130230513 | Assay Method for Alzheimer's Disease - A diagnostic test for preclinical and clinical Alzheimer's disease is based on plasma levels of Aβ | 2013-09-05 |
| 20130230514 | COMPOSITIONS OF PD-1 ANTAGONISTS AND METHODS OF USE - Methods of treating cancer and infectious diseases utilizing a treatment regimen comprising administering a compound that reduces inhibitory signal transduction in T cells, in combination with a potentiating agent, such as cyclophosphamide, to produce potent T cell mediated responses, are described. Compositions comprising the PD-1 antagonists and potentiating agents useful in the methods of the invention are also disclosed. | 2013-09-05 |
| 20130230515 | MYOSTATIN BINDING AGENTS - The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity. | 2013-09-05 |
| 20130230516 | TARGETED CRYPTOSPORIDIUM BIOCIDES - The present invention relates to fusion proteins comprising a microorganism targeting molecule (e.g., immunoglobulin) and a biocide. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in diverse fields. | 2013-09-05 |
| 20130230517 | ENGINEERED ANTIBODY-INTERFERON MUTANT FUSION MOLECULES - The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to fusion molecule constructs wherein a tumor associated antigen (TAA) antibody (Ab) serves as a targeting moiety to selectively deliver a cytokine to a tumor cell for purposes of killing or inhibiting the growth or proliferation of said tumor cell. In various embodiments, the engineered fusion molecules comprise a TAA Ab fused to an interferon-alpha (IFN-α) mutant molecule. The engineered Ab-IFN-α mutant fusion molecules of the present invention demonstrate improved therapeutic index and preserved or increased efficacy as compared to Ab-wildtype IFN-α fusion molecules, and/or demonstrate improved PK properties as compared to Ab-wildtype IFN-α fusion molecules. | 2013-09-05 |
| 20130230518 | METHODS FOR TREATING SJOGRENS SYNDROME BY ADMINISTERING A SOLUBLE CTLA4 MOLECULE - The present invention relates to compositions and methods for treating autoimmune diseases, such as Sjogren's syndrome, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands. | 2013-09-05 |
| 20130230519 | ANTI-SERUM ALBUMIN BINDING VARIANTS - The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-14-10, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts. | 2013-09-05 |
| 20130230520 | PHARMACEUTICAL COMPOSITION FOR TREATING BONE DISEASES WHICH COMPRISES PROTEIN COMPRISING FRIZZLED1, FRIZZLED2 OR FRIZZLED7 EXTRACELLULAR CYSTEINE-RICH DOMAIN - This invention relates to a pharmaceutical composition for treatment of a bone disease comprising, as an active ingredient, a protein comprising an extracellular cysteine-rich domain, which is from the Frizzled receptor selected from the group consisting of mammalian animal-derived Frizzled 1, Frizzled 2, and Frizzled 7 and has activity of increasing bone mass, bone density, and/or bone strength, or a mutant of such domain having sequence identity of 85% or higher to the amino acid sequence of the domain and having activity of increasing bone mass, bone density, and/or bone strength, or a vector comprising a nucleic acid encoding the protein. | 2013-09-05 |
| 20130230521 | Tumor-Targeting Monoclonal Antibodies to FZD10 and Uses Thereof - The present invention relates to an antibody or a fragment thereof which is capable of binding to a Frizzled homologue 10 (FZD10) protein, such as a mouse monoclonal antibody, a chimeric antibody and a humanized antibody. Also, the present invention relates to a method for treating and/or preventing FZD10-associated disease; a method for diagnosis or prognosis of FZD10-associated disease; and a method for in vivo imaging of FZD10 in a subject. | 2013-09-05 |
| 20130230522 | Complement Pathway Inhibitors Binding To C5 and C5A Without Preventing The Formation of C5B - The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an inhibitor molecule is the monoclonal antibody designated MAb137-26, which binds to a shared epitope of human C5 and C5a. These inhibitors may be used to inhibit the activity of C5a in treating diseases and conditions mediated by excessive or uncontrolled production of C5a. The inhibitor molecules are also useful for diagnostic detection of the presence/absence or amount of C5 or C5a. | 2013-09-05 |
| 20130230523 | METHODS FOR DETECTING TH1 CELLS - The inventors discovered that the adhesion molecule CAR, known to be localized in intracellular adhesion sites, functioned as an adhesion molecule for activated lymphocytes. Further, the inventors identified CARL, a novel CAR ligand expressed in lymphocytes, and clarified that the ligand was expressed selectively in Th1 cells. In addition, they found that anti-CAR antibodies could inhibit the adhesion of activated lymphocytes to CAR molecules. Thus, the present invention provides methods for detecting Th1 cells using CAR or anti-CARL antibodies, and methods of screening for inhibitors suppressing the adhesion of Th1 cells using the binding between CAR and CARL as an index. Furthermore, the present invention relates to methods of screening for inhibitors of the binding between CAR and CARL, antibodies that inhibit the binding between CAR and CARL, and therapeutic compositions comprising these antibodies. These are expected to be useful in diagnosing diseases, such as inflammation, in which infiltration of Th1 cells is involved, and in providing pharmaceutical agents for alleviating such diseases. | 2013-09-05 |
| 20130230524 | Protein Involved in Ovarian Cancer - The present invention relates to new uses of CDCP1 in the diagnosis, screening, treatment and prophylaxis of ovarian cancer. The invention also provides compositions comprising CDCP1, including vaccines, antibodies that are immunospecific for CDCP1 and agents which interact with or modulate the expression or activity of CDCP1 or which modulate the expression of the nucleic acid which codes for CDCP1. | 2013-09-05 |
| 20130230525 | PROTEIN COMPLEXES FOR ANTIGEN BINDING AND METHODS OF USE - Provided herein in certain embodiments are polypeptide complexes capable of binding to an antigen. Pharmaceutical compositions, method of using the polypeptide complexes are also provided. | 2013-09-05 |
| 20130230526 | KLEBSIELLA ANTIGENS - The present invention relates to an isolated nucleic acid molecule encoding an antigen, a vector comprising such nucleic acid molecule and a host cell comprising such vector. Furthermore, the invention provides antigens from | 2013-09-05 |
| 20130230527 | EMP2 ANTIBODIES AND THEIR THERAPEUTIC USES - The present invention provides methods and compositions useful in the treatment or prevention of | 2013-09-05 |
| 20130230528 | METHODS FOR DIAGNOSIS AND TREATMENT OF PROLIFERATIVE DISORDERS MEDIATED BY CD40 SIGNALING - Methods for identifying subjects having a cancer or pre-malignant condition that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing neoplastic cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent. | 2013-09-05 |
| 20130230529 | NOVEL PARAMYXOVIRUS AND USES THEREOF - Described herein are isolated | 2013-09-05 |
| 20130230530 | HUMAN ANTIBODIES THAT BIND CD22 AND USES THEREOF - The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure. | 2013-09-05 |
| 20130230531 | Human Antibodies to Clostridium difficile Toxins - The present invention provides fully human antibodies that bind to either toxin A or toxin B of | 2013-09-05 |
| 20130230532 | MYOMEGALIN VARIANT 8 AND USES THEREOF - The present invention provides a novel myomegalin isoform—myomegalin variant 8 (MMG8). The myomegalin variant 8 regulates microtubule organization at the Golgi apparatus, protein modification, secretion and trafficking, and cell proliferation. The present invention also provides nucleic acid molecules encoding the myomegalin isoforms, and vectors and host cells containing the nucleic acid molecules. Also provided are fusion constructs comprising the myomegalin isoform and antibodies that bind specifically to the myomegalin isoforms of the present invention. The present invention further provides uses of the myomegalin isoform as a diagnostic biomarker and as a target for screening for therapeutics for diseases such as cancer, diabetes, and lysosomal storage diseases. | 2013-09-05 |
| 20130230533 | METHODS OF TREATING SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) USING ANTI-CD48 ANTIBODIES - The present invention provides antibodies that bind to CD48 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human CD48. In certain embodiments, the antibodies of the present invention block the binding of CD48 to one or more CD48 receptor. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more CD48 biological activities, including the treatment of allergic conditions and other inflammatory conditions, e.g., systemic lupus erythematosus. | 2013-09-05 |
| 20130230534 | Interferon Receptor 1 Antibodies And Their Uses - The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention. | 2013-09-05 |
| 20130230535 | THERAPY-ENHANCING GLUCAN - This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer comprising administrating the above-described composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of vaccines. This invention also provides a method of treating a subject comprising administrating the above pharmaceutical composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of natural antibodies. This invention provides a composition comprising effective amount of glucan capable of enhancing host immunity. This invention also provides a composition comprising effective amount of glucan capable of enhancing the action of an agent in preventing tissue rejection. | 2013-09-05 |
| 20130230536 | ANTAGONISTIC HUMAN LIGHT-SPECIFIC HUMAN MONOCLONAL ANTIBODIES - Provided herein are antibodies that immunospecifically bind to an hLIGHT polypeptide; isolated nucleic acids encoding the antibodies; vectors and host cells comprising nucleic acids encoding the antibodies; methods of making the antibodies; and a method of treating a hLIGHT-mediated disease in a subject comprising administering to the subject the antibodies. In preferred embodiments, the anti-hLIGHT antibodies provided herein will ameliorate, neutralize or otherwise inhibit hLIGHT biological activity in vivo (e.g., the hLIGHT-mediated production or secretion of CCL20, IL-8 or RANTES from a cell expressing a hLIGHT receptor). Also provided herein is a method for the detection of hLIGHT in a sample as well as a method for ameliorating, neutralizing or otherwise inhibiting hLIGHT activity, e.g., in a human subject suffering from a disorder in which hLIGHT activity is detrimental. | 2013-09-05 |
| 20130230537 | CLOSTRIDIUM DIFFICILE-SPECIFIC ANTIBODIES AND USES THEREOF - The present invention is directed to | 2013-09-05 |
| 20130230538 | METHOD OF TREATING A PATIENT HAVING AN AUTOIMMUNE DISORDER BY ADMINISTERING BAFFR POLYPEPTIDE - Therapeutic regimens for administration of BAFF antagonists for treatment of immunologic and related disorders are described. Regimens involve a short-term BAFF antagonist administration course followed by an extended no-treatment period prior the round of administration. | 2013-09-05 |
| 20130230539 | Anti-Leukocyte Recruitment Therapy for the Treatment of Seizures and Epilepsy - Methods are provided for the prevention and treatment of seizures and epilepsy. It is shown herein that leukocyte recruitment plays a key role in the pathogenesis of epilepsy. Treatment with an agent that inhibits leukocyte recruitment has therapeutic and preventative effects in blocking recurrent seizures and epilepsy. | 2013-09-05 |
| 20130230540 | COMPOSITIONS MONOVALENT FOR CD28 BINDING AND METHODS OF USE - The disclosure relates to a monovalent polypeptide domain which specifically binds CD28, as well as to an antagonist of CD28, where the antagonist comprises a monovalent polypeptide domain which specifically binds CD28. This disclosure encompasses monovalent polypeptide domains comprising an antibody single variable domain that monovalently binds CD28. An antibody single variable domain that is monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a monovalent anti-CD28 antibody single variable domain consists of or comprises an antibody single variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the monovalent anti-CD28 antibody single variable domain is a human antibody single variable domain. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a monovalent anti-CD28 antibody single variable domain to the individual. | 2013-09-05 |
| 20130230541 | ANTI-IGF ANTIBODIES - Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer. | 2013-09-05 |
| 20130230542 | ROS-Activated Compounds as Selective Anti-Cancer Therapeutics - Provided are compounds according to the following Formula I: | 2013-09-05 |
| 20130230543 | ENGINEERED POLYPEPTIDE CONJUGATES AND METHODS FOR MAKING THEREOF USING TRANSGLUTAMINASE - The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates, toxin-(biocompatible polymer) conjugates, antibody-(biocompatible polymer) conjugates, and bispecific antibodies) comprising acyl donor glutamine-containing tags and amine donor agents. In one aspect, the invention provides an engineered Fc-containing polypeptide conjugate comprising the formula (Fc-containing polypeptide)-T-A, wherein T is an acyl donor glutamine-containing tag engineered at a specific site or comprises an endogenous glutamine made reactive by the Fc-containing polypeptide engineering, wherein A is an amine donor agent, and wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag or the endogenous glutamine. The invention also provides methods of making engineered polypeptide conjugates using transglutaminase. | 2013-09-05 |
| 20130230544 | NOVEL IMMUNOSTIMULATORY METHOD - This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety. | 2013-09-05 |
| 20130230545 | COMPOUNDS FOR TREATING BETA-AMYLOIDOSES - The present invention relates to the use of mimotopes in the treatment of diseases associated with β-amyloid formation and/or aggregation (β-Amyloidoses) including Alzheimer's disease, whereby said mimotopes are able to induce the in vivo formation of antibodies directed to Aβ1-40/42, AβpE3-40/42, Aβ3-40/42 and Aβ11-40/42. | 2013-09-05 |
| 20130230546 | Chimeric VEGF Peptides - Compositions for and methods of treating patients with malignancies associated with overexpression of VEGF, particularly ovarian cancer, are provided herein. The compositions include but are not limited to certain VEGF epitopes, multivalent peptides comprising the epitopes, and chimeric peptides comprising one or more of the epitopes and a T cell epitope. | 2013-09-05 |
| 20130230547 | METHODS AND COMPOSITIONS FOR PROSTATE CANCER IMMUNOTHERAPY - The present invention features methods and compositions (e.g., immune response stimulating peptides (e.g., ERG or SIM2 peptides), activated immune cells, antigen-presenting cells, and antibodies or antigen-binding fragments thereof) for generating an immune response for the treatment of cancer (e.g., prostate cancer). | 2013-09-05 |
| 20130230548 | TRUNCATED L1 PROTEIN OF HUMAN PAPILLOMAVIRUS TYPE 52 - Provided is a truncated L1 protein of Human Papillomavirus (HPV) Type 52 which, compared to a wild type HPV52 L1 protein, is truncated by 27-42 amino acids at the N-terminal. Also provided are a coding sequence of the truncated HPV52 L1 protein, a virus-like particle (VLP) comprising the protein, and a method of preparing the protein and the VLP using an | 2013-09-05 |
| 20130230549 | FOOT AND MOUTH DISEASE VIRUS WITH INCREASED STABILITY AND ITS USE AS VACCINE - The present invention provides a foot and mouth disease (FMD) virus having improved stability compared to the field isolate of the same subtype, wherein the virus comprises one or more amino acid mutations along a line of symmetry of the capsid structure. The present invention also relates to a vaccine comprising such an FMD virus and its use to prevent foot and mouth disease. | 2013-09-05 |
| 20130230550 | METHODS AND COMPOSITIONS INVOLVING PROTECTIVE STAPHYLOCOCCAL ANTIGENS - The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a | 2013-09-05 |
| 20130230551 | Allergy Inhibitor Compositions And Kits And Methods Of Using The Same - Compositions, methods, and kits for inhibiting an allergic response against an allergenic protein are disclosed. Compositions, methods and kits for inhibiting an allergic response against an a flea allergenic protein; a feline allergenic protein; a canine allergenic protein; a dust mite allergenic protein; a peanut allergenic protein; a Japanese cedar allergenic protein; and a | 2013-09-05 |
| 20130230552 | INFLUENZA VIRUSES WITH MUTANT PB2 GENE SEGMENT AS LIVE ATTENUATED VACCINES - The invention provides a recombinant biologically contained influenza virus that is a PB2 knockout virus, e.g., one that is useful to generate a multivalent vaccine, and methods of making and using that virus. | 2013-09-05 |
| 20130230553 | MODULATION OF IMMUNE RESPONSES BY THE POXVIRAL K4 PROTEIN - The present invention relates to compositions, methods, and uses involving the modulation of K4 protein activity, especially in the treatment of various diseases and in the enhancement of vaccination regimens. The invention relates to poxviruses having reduced or increased K4 protein activity, as well as methods of making and using these poxviruses. The invention further relates to K4 proteins and inhibitors of K4 protein activity, as well as methods for making and using them. | 2013-09-05 |
| 20130230554 | TARGETED GENE DELIVERY FOR DENDRITIC CELL VACCINATION - Methods and compositions are provided for delivery of a polynucleotide encoding a gene of interest, typically an antigen, to a dendritic cell (DC). The virus envelope comprises a DC-SIGN specific targeting molecule. The methods and related compositions can be used to treat patients suffering from a wide range of conditions, including infection, such as HIV/AIDS, and various types of cancers. | 2013-09-05 |
| 20130230555 | SYNTHETIC LIPID BIOLOGY FOR COMBINATORIAL ENGINEERING OF ENDOTOXIN - The present disclosure generally relates to genetic engineering of bacteria. More particularly, the present disclosure relates to genetic engineering of Gram-negative bacteria expressing different species of lipid A on their surface. In one embodiment, the present disclosure provides for an engineered strain of | 2013-09-05 |
